Cilia appear in a wide variety of cell types, including osteoclasts and osteoblasts, where they function as physiologic and biochemical sensors.
Cilia appear in a wide variety of cell types, including osteoclasts and osteoblasts, where they function as physiologic and biochemical sensors.
Christopher Jacobs, PhD, from Columbia University, discussed the interplay between mechanobiology and biomechanics in primary cilia at the 2014 American Society of Bone and Mineral Research Conference in Houston, Texas.
Individual cells and cell types encounter the outside world differently. Osteoclasts and osteoblasts react to outside forces imposed on them by activities such as strain, exercise, and sitting. Endothelial cells respond to the mechanical stress caused by laminar blood flow, and cellular mechanical transduction is at the center of atherosclerosis.
Primary cilia are single antenna-like structures emerging from each cell. As Dr Jacobs said, “they are not vestigial, not the appendix of the cell.” They specifically function as physiologic and biochemical sensors in cells as diverse as cholangiocytes, osteocytes, and chondrocytes.
In bone, primary cilia function in bone transduction and the lack of cilia interferes with PGE2 release in osteoblasts.
In his talk, Dr Jacobs said that biomechanical changes in the environment alter how the cell can use the cilium as a biochemical sensor. Primary cilia deflect with flow. As a cilium experiences variable timing and force of the flowing air or liquid to which it is exposed, it may change its organization and remodel as it bends.
The microtubular network anchoring the base of cilium becomes enhanced, and this sub-cellular structure seems to be a sensor that adapts to its environment. Primary cilia stiffness can be modulated, as can torsional stiffness. Increased stiffness correlates with the degree of biomechanical sensitivity.
According to Dr Jacobs, future directions for the study of cilia include answering questions about the nature of calcium and other biochemical channels in cilia compared with other cell types. He is also exploring the role of cilia in mesenchymal stem cells.
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More